MabThera/Rituxan

ABPI hits out at ‘punitive’ UK medicines cost controls

set a target of £300m in savings from biosimilars in the next three years – led by cheaper versions of drugs such as Herceptin, MabThera and Humira – but Warwick Smith says the

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

Roche has seen revenues from blockbuster MabThera/Rituxan slashed in half in Europe thanks to growing biosimilar competition in the second quarter.

Celgene’s Revlimid gets a win in late-stage lymphoma

Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates. Celgene has new phase III data that could add yet another string to blockbuster Revlimid’s bow – as a treatment ... a significant increase in progression-free survival (PFS) compared

Roche keeps Venclexta train rolling with new leukaemia filing

population was expanded after the regulator okayed its use alongside Roche’s Rituxan (rituximab) for all relapsed/refractory CLL patients based on the MURANO trial results.

CTI slumps as Servier-partnered lymphoma drug fails

The PIX306 trial paired Pixuvri (pixantrone) – already sold in some European markets as a monotherapy for hard-to-treat NHL – with Roche’s MabThera (rituximab) and compared it to MabThera plus

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]